Vanguard Capital Management’s Cadrenal Therapeutics CVKD Stock Holding History
Bought
Maintained
Sold
Other funds holding CVKD
Vanguard Capital Management's CVKD Position: Q3 2026 in Review
Vanguard Capital Management reduced its Cadrenal Therapeutics (CVKD) stake by 66% in Q3 2026, selling an estimated $60.4K and leaving 16,859 shares worth $18.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3989.
Vanguard Capital Management first reported a position in CVKD in Q1 2026 and has held it in 3 quarters since. The position peaked at $231K in Q1 2026. 26 funds tracked by Wall St. Rank hold CVKD as of Q3 2026.
- Vanguard Capital Management held 16,859 shares of Cadrenal Therapeutics worth $18.2K as of Q3 2026.
- Vanguard Capital Management sold 33,278 Cadrenal Therapeutics shares in Q3 2026, an estimated $60.4K.
- Cadrenal Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3989 holding.
- Vanguard Capital Management first reported a position in Cadrenal Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Cadrenal Therapeutics position peaked at $231K in Q1 2026.
- 26 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.